Background: Anticoagulation for venous thromboembolism (VTE) is required for at least
three to six months; however, it is advisable to extend the duration in certain cases, in which …

Background: Direct oral anticoagulants (DOACs) are widely used for the treatment and
secondary prophylaxis of venous thromboembolism (VTE). Nowadays, DOACs represent the …

Background: In patients with venous thromboembolism (VTE), the study of the case fatality
rate (CFR) of VTE recurrences and bleeding complications may be of help to balance the …

Abstract Introduction Direct oral anticoagulants (DOACs) effectively prevent recurrent
venous thromboembolism (VTE). However, it is unknown which agents should be used to …

Currently available anticoagulants have limitations for long-term treatment of venous
thromboembolism (VTE). We have evaluated the efficacy and safety of direct oral …

Objective To examine and compare the safety and efficacy of extended treatment with
dabigatran, apixaban, rivaroxaban and warfarin in patients with unprovoked venous …

Introduction The frequency and case fatality of venous thromboembolism (VTE) and major
bleeding during the initial 3 months of therapy in those treated for symptomatic VTE with …

Essentials• In venous thromboembolism (VTE), benefits of extended treatment are balanced
by bleeding risks.• This is a meta‐analysis of reduced‐dose direct oral anticoagulants …

After completing anticoagulation therapy for acute venous thromboembolism (VTE), patients
with unprovoked VTE are at increased risk of recurrent thrombotic events. Recent studies …

Thank you to our colleagues Herold and Bauersachs for their commentary. The
consideration for extended anticoagulation in patients with unprovoked deep vein …